Bioactive peptides based on diversity libraries, supramolecular chemistry and rational design: A new class of peptide drugs. Introduction

Molecular Diversity

Volumn 8, Issue 2, 2004, Pages 57-59

  Meloen, Rob ^a,b   Timmerman, Peter ^a   Langedijk, Hans ^a  

^a Pepscan Systems   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PEPTIDE LIBRARY;

BINDING SITE; DRUG DESIGN; DRUG FORMULATION; GENOMICS; MOLECULAR INTERACTION; MOLECULAR SIZE; MOLECULE; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG INDUSTRY; PEPTIDE LIBRARY; PEPTIDES; RECOMBINANT PROTEINS;

EID: 3543005927     PISSN: 13811991     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MODI.0000025698.16766.11     Document Type: Review

References (18)

1. Ruoslahti, E. and Piersbacher M. D., Arg-Gly-Asp: A versatile cell recognition signal, Cell, 44 (1986) 517-518.
2. Antoni, G., Presentini, R., Perin, F., Tagliabue, A., Ghiara, P., Censin, S., Volpini, G., Villa, L. and Boraschi, D., Short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity, J. Immunlogy, 137 (1986) 3202-3204.
3. Keane, A. M., Trayer, I. P., Levine, B. A., Zeugner, C. and Ruegg, J. C., Peptide mimitics of an actin site on myosin span two functional domains on actin, Nature, 344 (1990) 265-268.
4. Roland, J., Berezov, A., Greene, M. I., Murali, R., Piatier-Tonneau, D., Devaux, C. and Briant, L., The synthetic CD4 exocyclic CDR3.AME(82-89) inhibits NF-kappaB nuclear translocation, HIV-1 promoter activation, and viral gene expression, DNA Cell Biol., 18 (1999) 819-828.
5. Dennis, M. S., Quan, C. R. M. and Lazarus, R. A., Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa, Biochemistry, 40 (2001) 9513-9521.
6. Khan, N. A., Khan, A., Savelkoul, H. F and Benner, R., Inhibition of septic shock in mice by an oligopeptide from the beta-chain of human chorionic gonadotrophin hormone, Hum. Immunol., 63 (2001) 1-7.
7. Orning, L., Fischer, P. M., Hu, C. K., Agner, E., Engebretsen, M., Husbyn, M., Petersen, L. B., Orvim, U., Llinas, M. and Sakriassen, K. S., A cyclic peptapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation thrombus formation, Thromb. Haemost., 87 (2002) 13-21.
8. Adessi, C., Frossard, M. J., Boissard, C., Fraga, S., Bieler, S., Ruckle, T., Vilbois, F., Robinson, S. M., Mutter, M., Banks, W. A. and Soto, C., Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease, J. Biol. Chem., 278 (2003) 13905-13911.
9. Betts, R., Weinsheimer, S., Blouse, G. E. and Anagli J., Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT, J. Biol. Chem., 278 (2003) 7800-7809.
10. Gomez, I., Miranda-Rios, J., Rudino-Pinera, E., Oltean, D. I., Gill, S. S., Bravo, A. and Soberon, M., Hydropathic complementarity determines interaction of epitope (869)HITDTNNK(876) in Manduca sexta Bt-R(1) receptor with loop 2 of domain II of Bacillus thuringiensis Cry1A toxins, J. Biol. Chem., 277 (2002) 30137-30143.
11. Tsumoto, K., Misawa, S., Ohba, Y., Ueno, T., Hayashi, H., Kasai, N., Watanabe, H., Asano, R. and Kumagai, I., Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: Tolerance of a CDR peptide to conformational changes of a target, FEBS Lett., 525 (2002) 77-82.
12. Monfardini, C., Canziani, G., Plugariu, C., Kieber Emmons, T., Godillot, A. P., Kwah, J., Bajgier, J., Chaiken, I. and Williams, W. V., Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF), Curr. Pharm. Des., 8 (2002) 2185-2199.
13. Wells, J. A., Hormone mimicry, Science, 273 (1996) 449-450.
14. Cwirla, S. E., Balasubramanian, P., Duffin, D. J., Wagstrom, C. R., Gates, C. M., Singer, S. C., Davis, A. M., Tansik, R. L., Mattheakis, L. C., Boytos, C. M., Schatz, P. J., Baccanari, D. P., Wrighton, N. C., Barrett, R. W. and Dower, W. J., Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine, Science, 276 (1997) 1696-91997.
15. Takasaki, W., Kajino, Y., Kajino, K., Murali, R. and Greene, M. I., Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor, Nat. Biotechnol., 15 (1997) 1266-1270.
16. Uings, I. J., Balasubramanian, P., McLoughlin, P. G., Yin, Q., Dash, L., Beresford, A., Kearney, S., Barrett, R. W., McKinnon, M. and England, B. P., Modified peptide antagonists of interleukin 5 exhibit extended in vivo persistence but restricted species specificity, Cytokine, 7 (2001) 10-9.
17. Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A. and Lowman, H. B., Stable 'zeta' peptides that act as potent antagonists of the high-affinity IgE receptor, PNAS, 99 (2002) 1303-1308.
18. James, T-20 and Trimiris, AIDS Treat News, 293 (1998) 1-6.